Literature DB >> 2508541

Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa.

J Trias1, J Dufresne, R C Levesque, H Nikaido.   

Abstract

The outer membrane of imipenem-resistant mutants of Pseudomonas aeruginosa was shown to have decreased permeability to imipenem but not to cephaloridine. These experiments were performed with intact cells and liposomes containing imipenem-hydrolyzing beta-lactamase derived from Pseudomonas maltophilia, in both cases utilizing an imipenem concentration of 50 microM. In contrast, liposome swelling assays using imipenem at 8 mM detected no significant difference between the imipenem-resistant mutants and their parents. It was found that the outer membrane of P. aeruginosa has a saturable specific channel through which imipenem travels mainly at low concentrations, whereas at high concentrations this pathway is obscured by diffusion through nonspecific porin channels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508541      PMCID: PMC172625          DOI: 10.1128/AAC.33.8.1202

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  [Not Available].

Authors:  G N COHEN; H V RICKENBERG
Journal:  Ann Inst Pasteur (Paris)       Date:  1956-11

2.  Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

Authors:  J P Quinn; E J Dudek; C A DiVincenzo; D A Lucks; S A Lerner
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

3.  Imipenem resistance in Pseudomonas aeruginosa is due to diminished expression of outer membrane proteins.

Authors:  K H Büscher; W Cullmann; W Dick; S Wendt; W Opferkuch
Journal:  J Infect Dis       Date:  1987-10       Impact factor: 5.226

4.  Resistance of Pseudomonas aeruginosa to imipenem is independent of beta-lactamase production.

Authors:  K H Büscher; W Cullmann; W Opferkuch
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

5.  Penetration of beta-lactams through Pseudomonas aeruginosa porin channels.

Authors:  A J Godfrey; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

6.  Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein.

Authors:  K H Büscher; W Cullmann; W Dick; W Opferkuch
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

7.  Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12.

Authors:  F Yoshimura; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

8.  Study of in vitro selected resistance of Pseudomonas aeruginosa to cefoperazone, ceftazidime, azthreonam and imipenem.

Authors:  P Van der Auwera; M Husson; G Bulliard
Journal:  Drugs Exp Clin Res       Date:  1986

9.  Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem.

Authors:  J H Andrew; D Greenwood
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

10.  Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila.

Authors:  K Shannon; A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

View more
  37 in total

Review 1.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

2.  Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa.

Authors:  J Trias; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  In vitro activity of E1040 against imipenem-resistant Pseudomonas aeruginosa strains.

Authors:  M Watanabe; E Inoue; K Katsu; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.

Authors:  C Dib; J Trias; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

Review 5.  Susceptibility testing of anaerobic bacteria: myth, magic, or method?

Authors:  H M Wexler
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

6.  A convenient method to screen for carbapenemase-producing Pseudomonas aeruginosa.

Authors:  Damien Fournier; Pauline Garnier; Katy Jeannot; Amélie Mille; Anne-Sophie Gomez; Patrick Plésiat
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

7.  The Acinetobacter Outer Membrane Contains Multiple Specific Channels for Carbapenem β-Lactams as Revealed by Kinetic Characterization Analyses of Imipenem Permeation into Acinetobacter baylyi Cells.

Authors:  Jorgelina Morán-Barrio; María M Cameranesi; Verónica Relling; Adriana S Limansky; Luciano Brambilla; Alejandro M Viale
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem.

Authors:  G L Cooper; A Louie; A L Baltch; R C Chu; R P Smith; W J Ritz; P Michelsen
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

9.  Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem.

Authors:  E H Lee; M H Nicolas; M D Kitzis; G Pialoux; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.

Authors:  Koichi Tanimoto; Haruyoshi Tomita; Shuhei Fujimoto; Katsuko Okuzumi; Yasuyoshi Ike
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.